AYTU BioPharma, Inc. - AYTU STOCK NEWS

Aytu BioScience, Inc. (NASDAQ:AYTU) announced a conference call to discuss its operational results for the fiscal second quarter ending December 31, 2020, scheduled for February 11, 2021, at 4:30 PM ET. During this call, the company will highlight its quarterly accomplishments and future business strategies. Aytu markets several FDA-approved products, including Natesto, ZolpiMist, and Tuzistra XR, along with a range of pediatric medications. Additionally, Aytu is actively involved in COVID-19 testing and has licensed Healight™ technology for potential respiratory treatments.

Aytu BioScience, a specialty pharmaceutical company, announced the completion of a safety study for its Healight™ ultraviolet A light catheter technology. This study focused on critically ill COVID-19 patients on mechanical ventilation in the U.S. The safety data will be presented to the FDA for potential treatment of SARS-CoV-2. CEO Josh Disbrow highlighted this as a significant milestone, aiming for continued FDA discussions. This technology is designed to reduce viral and bacterial loads, with promising pre-clinical findings paving the way for human trials.

Aytu BioScience, a specialty pharmaceutical company, announced its presentation at the LD Micro Virtual Investor Conference on December 15, 2020, at 2:20 PM ET. This conference features a new format, allowing each company a 10-minute presentation followed by a 10-minute Q&A session with investors and analysts. Aytu's portfolio includes unique FDA-approved products addressing significant patient needs in primary care and pediatrics. For more details, visit the webcast.

Aytu BioScience (NASDAQ:AYTU) announced an underwriting agreement with H.C. Wainwright & Co. for a public offering of 1,666,667 shares at $6.00 per share. Expected gross proceeds are approximately $10 million, aimed at working capital and corporate purposes. Furthermore, the underwriter has a 30-day option to purchase an additional 250,000 shares. This offering follows the company's previously filed registration statement and is subject to customary closing conditions.

Aytu BioScience (NASDAQ:AYTU) will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on November 18, 2020, at 1:45 PM ET / 6:45 PM GMT. The presentation will highlight the company's focus on novel pharmaceutical products, including FDA-approved treatments for low testosterone and sleep aids. A webcast of the presentation will be available online. Aytu's portfolio includes various prescription and consumer healthcare products aimed at significant patient needs, along with COVID-19 testing solutions.

Aytu BioScience (NASDAQ:AYTU) will announce its operational results for Q1 FY2021, ending September 30, 2020, on November 12, 2020, at 4:30 PM ET. The conference call will address the company’s recent achievements and future strategies. Aytu’s portfolio includes unique FDA-approved products like Natesto, ZolpiMist, and Tuzistra XR. Additionally, the company has a rapid COVID-19 testing solution and has licensed the Healight technology for respiratory infections. A live webcast will be available for 90 days on their website.

Aytu BioScience reported record fiscal Q4 2020 revenue of $14.9 million, an increase of 82% sequentially and 766% year-over-year, surpassing its entire fiscal 2019 revenue. The company achieved $6.9 million in Consumer Health and $7.9 million in Rx net revenue. Adjusted EBITDA loss was narrowed to ($1.7 million), down from ($3.7 million) in Q4 2019, with $48.3 million in cash on hand. CEO Josh Disbrow highlighted strong revenue performance and positive momentum moving into fiscal 2021, driven by the integration of Aytu and Innovus businesses and upcoming product launches.

Aytu BioScience (NASDAQ:AYTU) will announce its operational results for the fiscal fourth quarter and full year ending June 30, 2020, during a conference call on October 6, 2020, at 4:30 PM ET. Key products include FDA-approved testosterone nasal spray, sleep aid, and other pediatric formulations. The company also distributes COVID-19 rapid tests and is developing Healight technology for respiratory infections. The Form 10-K will be filed post-market on the same day, providing further insights into Aytu’s performance and strategy.

Aytu BioScience (NASDAQ:AYTU) announced the rescheduling of its fourth quarter and FY 2020 conference call, originally set for September 24, 2020, due to additional workload from the Innovus Merger and the Cerecor pediatric portfolio acquisition. The call will discuss record revenue for the fourth quarter and full fiscal year, alongside business progress updates. Aytu's product portfolio includes innovative prescription products targeting significant patient needs, including treatments for low testosterone and pediatric health issues.